SAT-429 Final Results from the First in Man Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable sst2-Selective, Nonpeptide Somatostatin Biased Agonist, for the Treatment of Acromegaly: Safety, Pharmacokinetics, Pharmacodynamics, and Midazolam Drug Interaction in Healthy Volunteers

Injected depot formulations of somatostatin peptide analogs are routinely used to treat acromegaly and neuroendocrine tumors (NETs). CRN00808 is a small molecule nonpeptide selective somatostatin receptor 2 agonist whose safety, pharmacokinetics (PK), and pharmacodynamics (PD) has been characterized...

Descripción completa

Detalles Bibliográficos
Autores principales: Madan, Ajay, Zhu, Yun Fei, Markison, Stacy, Betz, Stephen, Krasner, Alan, Luo, Rosa, Oltersdorf, Tilman, Jochelson, Theresa, Lickliter, Jason, Struthers, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552001/
http://dx.doi.org/10.1210/js.2019-SAT-429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552001/
http://dx.doi.org/10.1210/js.2019-SAT-429

Ejemplares similares